Profile data is unavailable for this security.
About the company
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
- Revenue in JPY (TTM)133.26bn
- Net income in JPY10.77bn
- Incorporated1958
- Employees2.00k
- LocationKyorin Pharmaceutical Co Ltd8F-10F, Nikkei Bldg., 1-3-7, Ote-machiCHIYODA-KU 100-0004JapanJPN
- Phone+81 363749700
- Fax+81 335254780
- Websitehttps://www.kyorin-pharm.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 56.30bn | 1.76k | 23.70 | 1.15 | 8.95 | 1.03 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| Oncolys Biopharma Inc | 28.55m | -2.06bn | 64.21bn | 35.00 | -- | 16.04 | -- | 2,249.25 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| Cuorips Inc | 360.02m | -661.72m | 69.93bn | 56.00 | -- | 13.31 | -- | 194.23 | -81.32 | -81.32 | 44.45 | 635.67 | 0.0642 | 3.87 | 247.60 | 6,428,875.00 | -11.85 | -- | -12.15 | -- | 77.23 | -- | -184.50 | -- | 42.03 | -- | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 68.70bn | 4.91bn | 69.98bn | 1.63k | 14.07 | 1.01 | 9.03 | 1.02 | 172.92 | 172.92 | 2,421.07 | 2,420.68 | 0.6729 | 1.37 | 3.62 | 42,094,980.00 | 4.93 | 5.50 | 6.64 | 7.07 | 48.33 | 47.56 | 7.32 | 7.98 | 1.23 | 75.35 | 0.1551 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
| Nxera Pharma Co Ltd | 28.70bn | -6.14bn | 79.28bn | 374.00 | -- | 1.21 | -- | 2.76 | -68.13 | -68.13 | 318.44 | 725.52 | 0.1936 | 1.47 | 4.57 | 76,737,970.00 | -4.14 | -1.71 | -4.63 | -1.85 | 71.17 | 84.07 | -21.41 | -10.93 | 2.55 | -11.73 | 0.4902 | -- | 125.87 | 24.28 | 32.74 | -- | 40.57 | -- |
| JCR Pharmaceuticals Co Ltd | 37.55bn | -2.44bn | 86.37bn | 987.00 | -- | 1.75 | 185.74 | 2.30 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Kyorin Pharmaceutical Co Ltd | 133.26bn | 10.77bn | 100.11bn | 2.00k | 8.91 | 0.6908 | 6.51 | 0.7513 | 187.40 | 187.40 | 2,319.59 | 2,417.37 | 0.6927 | 1.08 | 2.93 | 66,695,200.00 | 5.60 | 3.34 | 7.03 | 4.16 | 45.32 | 45.89 | 8.08 | 5.11 | 2.05 | -- | 0.1746 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Katakura Industries Co Ltd | 40.98bn | 5.84bn | 110.75bn | 941.00 | 17.25 | 1.10 | 12.59 | 2.70 | 182.30 | 182.30 | 1,278.51 | 2,853.06 | 0.2926 | 2.15 | 6.42 | 43,545,160.00 | 4.27 | 2.60 | 5.20 | 3.57 | 36.16 | 37.98 | 14.59 | 9.44 | 2.63 | -- | 0.0807 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Zeria Pharmaceutical Co Ltd | 86.61bn | 7.26bn | 113.13bn | 1.75k | 13.43 | 1.02 | 7.77 | 1.31 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Mochida Pharmaceutical Co Ltd | 111.92bn | 6.42bn | 136.28bn | 1.51k | 20.67 | 0.966 | 14.52 | 1.22 | 181.16 | 181.16 | 3,156.95 | 3,876.77 | 0.6427 | 1.67 | 3.02 | 74,214,190.00 | 3.69 | 4.50 | 4.47 | 5.44 | 48.43 | 52.49 | 5.74 | 6.87 | 2.85 | -- | 0.0678 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
Data as of Feb 13 2026. Currency figures normalised to Kyorin Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
21.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kopernik Global Investors LLCas of 15 Dec 2025 | 4.58m | 7.64% |
| Amundi Japan Ltd.as of 05 Feb 2026 | 1.64m | 2.74% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.45m | 2.42% |
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 1.31m | 2.19% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 904.20k | 1.51% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 889.89k | 1.48% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 583.00k | 0.97% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 560.00k | 0.93% |
| Janus Henderson Investors (Singapore) Ltd.as of 31 Dec 2025 | 468.20k | 0.78% |
| Paradice Investment Management LLCas of 30 Sep 2025 | 277.60k | 0.46% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
